Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)
This is an open-label, multi-center expanded access program designed to provide access to Copper Cu 64 Dotatate for the detection, localization, and monitoring of NETs to patients that did not have access during the Phase 3 Trial.
Neuroendocrine Tumors
DIAGNOSTIC_TEST: Copper Cu 64 Dotatate
The objective of this trial is to provide patients with confirmed or suspicion of NET access to Copper Cu 64 Dotatate for the detection, localization, and monitoring of SSTR expressing NETs, bridging the gap between investigational product availability in clinical studies and marketed product availability following US Food and Drug Administration (FDA) approval.